Atimos
Instructions for use:
- 1. Release form and composition
- 2. Indications for use
- 3. Contraindications
- 4. Method of application and dosage
- 5. Side effects
- 6. Special instructions
- 7. Drug interactions
- 8. Terms and conditions of storage
Atimos is a bronchodilating drug, a selective β 2 -adrenoreceptor agonist with low affinity for β 1 -adrenergic receptors.
Release form and composition
Atimos is produced in the form of a metered aerosol for inhalation, which is a colorless or slightly yellow transparent solution (100 or 120 doses in aluminum cans with an inhaler, one can in a cardboard box).
Composition of 1 dose of aerosol:
- active substance: formoterol fumarate - 12 mcg;
- auxiliary components: hydrochloric acid, ethanol, norflurane (1,1,1,2-tetrafluoroethane).
Indications for use
Atimos is used to treat and prevent bronchospasm caused by cold air, exercise or allergens, as well as bronchospasm in patients with bronchial asthma.
The drug is also prescribed for the treatment and prevention of bronchial obstruction in people with chronic obstructive pulmonary disease.
Contraindications
Absolute:
- lactation period;
- children under 12 years of age (since the safety and efficacy of the drug in children under 12 years of age have not been established);
- hypersensitivity to the main or auxiliary components of the drug.
Relative (Atimos is used with caution):
- violation of the heart rhythm;
- cardiac ischemia;
- atrioventricular block III degree;
- chronic heart failure (decompensation stage);
- hypertrophic obstructive cardiomyopathy;
- exacerbation of the course of arterial hypertension;
- idiopathic subaortic stenosis;
- occlusive vascular diseases, especially of an atherosclerotic nature;
- Congenital or drug-induced lengthening of the QT interval (QT c > 0.44 seconds);
- hyperplasia of the prostate;
- thyrotoxicosis;
- refractory diabetes mellitus;
- pheochromocytoma;
- glaucoma;
- period of pregnancy.
Method of administration and dosage
Aerosol Atimos is intended for inhalation use in adult patients and adolescents over 12 years old.
Recommended doses:
- bronchial asthma: 1 dose (12 mcg) twice a day (morning and evening). If necessary, the dose can be doubled to relieve symptoms (24 mcg in the morning, 24 mcg in the evening). If such a need arises more than 2 days a week, this indicates a worsening of the course of asthma. In this case, it is necessary to consult a doctor who will review the prescribed treatment. The maximum daily dose is 48 μg (4 doses);
- prevention of bronchospasm caused by exercise or contact with an allergen: 15 minutes before provocation in an amount of 12 μg (1 dose). Persons with severe forms of bronchial asthma may require 2 inhalation doses (24 μg);
- chronic obstructive pulmonary disease (Atimos is used in patients over 18 years of age): 1-2 doses (12-24 μg) twice a day. The maximum daily dose is 48 μg, single dose is 24 μg.
Before the first spraying, as well as if the inhaler has not been used for 3 days or more, after removing the protective cap from the mouthpiece, you should make a test press and spray the drug into the air to make sure the inhaler is working properly.
After that, take the mouthpiece in your mouth and clasp it tightly with your lips, exhale through your nose. Then inhale slowly and deeply, simultaneously pressing on the end of the can. After inhaling, you must hold your breath as long as possible.
It is recommended to rinse the mouthpiece with warm water as it gets dirty.
In children, Atimos is used under adult supervision. To prevent inhalation through the nose during inhalation, the baby's nostrils can be pinched with the thumb and forefinger.
Side effects
- digestive system: dry mouth, change in taste, nausea;
- respiratory system: cough, paradoxical bronchospasm, shortness of breath, exacerbation of bronchial asthma;
- cardiovascular system: palpitations, decreased blood pressure, tachyarrhythmia, tachycardia, angina pectoris, cardiac arrhythmias, prolongation of the QTc interval;
- lymphatic system and blood: thrombocytopenia;
- central and peripheral nervous system: headache, anxiety, insomnia, dizziness, nervousness, anxiety, agitation, sleep disturbances, agitation, hallucinations, behavioral disorders;
- musculoskeletal system: tremors, muscle cramps, muscle pain;
- metabolism and nutrition: hyperglycemia, hypokalemia;
- urinary system: nephritis;
- skin and subcutaneous tissue: increased sweating, rash;
- laboratory parameters: an increase in the concentration of insulin, glycerin, free fatty acids and ketone bodies in the blood;
- allergic reactions: urticaria, itching, angioedema, exanthema;
- local reactions: irritation of the oropharynx;
- other reactions: weakness.
With strict adherence to the dosage regimen, the likelihood of side effects is significantly reduced.
special instructions
When prescribing the drug Atimos, the need for anti-inflammatory therapy should be assessed, since with the systematic use of inhaled adrenomimetics, patients with bronchial asthma should be systematically prescribed anti-inflammatory drugs.
Atimos is not intended for the relief of acute attacks of bronchial asthma. In this case, short-acting beta 2 -adrenomimetics should be used.
In the treatment of bronchial asthma, the drug should be used only as an adjunct to inhaled glucocorticosteroids. When adding it to the treatment regimen, you should not cancel or change the dose of glucocorticosteroids used.
If the symptoms of the disease persist or intensify, as well as in the case of the inability of the drug Atimos to effectively weaken them, we can talk about the aggravation of the course of the underlying disease, which requires the need to revise the treatment.
With the development of paradoxical bronchospasm, the drug should be urgently discontinued and alternative therapy should be prescribed.
The ethanol content in the preparation is insignificant - less than 100 mg per one inhalation dose.
When using Atimos for non-medicinal purposes, a doping effect is caused and during a doping test, the reaction will be positive.
Due to the possibility of side effects from the nervous system (dizziness, tremors, hallucinations) during treatment, care must be taken when driving or working with other potentially dangerous mechanisms.
Drug interactions
With simultaneous use with class IA antiarrhythmic drugs (disopyramide, quinidine, novocainamide) and class III (amiodarone, sotalol), antihistamines, tricyclic antidepressants, pentamidine, vancomycin, bepridil, phenothiazines, monoamine oxidase inhibitors, and possibly intravenous sultopricantromine lengthening the QT interval and increasing the risk of ventricular arrhythmias.
Other adrenergic medications can worsen the side effects of Atimos.
Co-administration with glucocorticosteroids, diuretics or xanthines can lead to an increase in the potential hypokalemic effect of beta 2 -adrenomimetics.
Atimos is not recommended for concomitant use with beta-blockers (including eye drops), as they can reduce its effect.
Since the drug contains ethanol, it is possible for an interaction to occur in persons with hypersensitivity who are taking metronidazole or disulfiram.
Terms and conditions of storage
Store away from direct sunlight and heating devices at a temperature of 2-8 ° C. The aerosol must not be frozen. Keep out of the reach of children. The shelf life is 1.5 years.
The aerosol can should not be punctured, thrown into a fire (even after use), or exposed to high temperatures. The drug must be used within 3 months after the first use.
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
